BRAF and hematocrit: A systematic review showed that BRAF^V600E mutations are significantly less frequent in PTC with HT (OR ≈0.45) than in conventional PTC, which may underlie the less aggressive phenotype and explain the slow clinicopathological course of PTC-HT positive [34].